Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
JPMA-Journal of Pakistan Medical Association. 2004; 54 (4): 202-206
in English | IMEMR | ID: emr-175602

ABSTRACT

Objective: To study the prevalence of hepatitis C virus in lymphoproliferative disorders


Methods: A case control prospective study was performed on 143 patients with lymphoproliferative disorders and 29 patients with non-hematological malignancies were taken as controls. All the patients in both groups were analyzed for various risk factors for infection with hepatitis C virus and were tested for the presence of hepatitis C virus antibody [anti HCV], cryoglobulins and rheumatoid factor antibody. Hepatitis C viremia was documented by detection of HCV RNA by polymerase chain reaction


Results: There was no significant difference for risk factors for hepatitis C virus infection in both the groups except for the increase in number of surgical procedures being carried out in the control group. There was no significant difference in the presence of rheumatoid factor antibody in both the groups and cryoglobulins were not positive in any individual. Five percent patients with lymphoproliferative disorders and 3.4% with non-hematological malignancies were positive for anti HCV. HCV RNA was detected in 29.2% cases and 31.0% in controls


Conclusion: There was no association between hepatitis C virus infection and lymphoproliferative disorder in our population. However, further studies are required from this region to establish any causal relationship between hepatitis C virus infection and lymphoproliferative disorder

2.
JPMA-Journal of Pakistan Medical Association. 2004; 54 (5): 249-51
in English | IMEMR | ID: emr-66962

ABSTRACT

To evaluate the various clinical and laboratory parameters of Polycythemia vera and idiopathic erythrocytosis in order to differentiate between two entities at the Aga Khan University Hospital. Twenty six patients of polycythemia vera and 34 patients of idiopathic erythrocytosis were analyzed with respect to clinical features and laboratory findings. Patients with idiopathic erythrocytosis were males with a mean age of 41 years and no splenomegaly. Patients with polycythemia were older males and females with splenomegaly, red cell count of mor than 6.5 million/cmm, haematocrit 55%, leucocytosis, thrombocytosis and low erythropoietin level. Based on the above-mentioned findings, we suggest that polycythemia vera and idiopathic erythrocytosis are separate entities and the diagnosis of these can be made on the basis of clinical and laboratory parameters


Subject(s)
Humans , Male , Female , Polycythemia Vera/physiopathology , Polycythemia/diagnosis , Erythrocyte Count , Leukocyte Count , Diagnosis, Differential , Cross-Sectional Studies
3.
JPMA-Journal of Pakistan Medical Association. 2004; 54 (5): 251-4
in English | IMEMR | ID: emr-66963

ABSTRACT

To study the frequency of HLA DR2 status of patients with aplastic anemia and their response to immunosuppressive therapy at a tertiary care hospital. Thirty eight consecutive patients of acquired aplastic anemia were evaluated with respect to demographic features, severity of HLA DR2 status and response outcome to immunosuppressive therapy. The mean age of the patients was 24.6 years + 16.4 with a male to female ratio of 2.8:1. Positivity of HLA DR2 was markedly high in acquired aplastic anemia patients. Twenty four [65%] out of 38 patients as compared to 45 [15%] of 300 healthy controls [p<0.0001] were positive for HLA DR2. Response to immunosuppressive therapy, which included antilymphocyte globulin, cyclosporin and methylprednisolone, was available in sixteen HLA DR2 positive patients and was found satisfactory in 12/16 [75%] patients. HLA DR2 was significantly higher in patients with acquired aplastic anemia and favourable response to immunosuppressive therapy was also associated with HLA DR2 positivity


Subject(s)
Humans , Male , Female , Anemia, Aplastic/immunology , HLA-DR2 Antigen/drug effects , HLA-DR2 Antigen/metabolism , Immunosuppressive Agents/pharmacology , Polymerase Chain Reaction , Histocompatibility Testing , Cross-Sectional Studies
4.
JPMA-Journal of Pakistan Medical Association. 2001; 51 (10): 360-362
in English | IMEMR | ID: emr-57343
SELECTION OF CITATIONS
SEARCH DETAIL